Works matching AU List, Alan F.

Results: 72
    1

    AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report.

    Published in:
    Biomarker Research, 2020, v. 8, n. 1, p. 1, doi. 10.1186/s40364-020-00208-1
    By:
    • Pogosova-Agadjanyan, Era L.;
    • Moseley, Anna;
    • Othus, Megan;
    • Appelbaum, Frederick R.;
    • Chauncey, Thomas R.;
    • Chen, I-Ming L.;
    • Erba, Harry P.;
    • Godwin, John E.;
    • Jenkins, Isaac C.;
    • Fang, Min;
    • Huynh, Mike;
    • Kopecky, Kenneth J.;
    • List, Alan F.;
    • Naru, Jasmine;
    • Radich, Jerald P.;
    • Stevens, Emily;
    • Willborg, Brooke E.;
    • Willman, Cheryl L.;
    • Wood, Brent L.;
    • Zhang, Qing
    Publication type:
    Article
    2
    3
    4
    5
    6

    Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium.

    Published in:
    Cancer (0008543X), 2015, v. 121, n. 6, p. 876, doi. 10.1002/cncr.29145
    By:
    • Jabbour, Elias J.;
    • Garcia‐Manero, Guillermo;
    • Strati, Paolo;
    • Mishra, Asmita;
    • Al Ali, Najla H.;
    • Padron, Eric;
    • Lancet, Jeffrey;
    • Kadia, Tapan;
    • Daver, Naval;
    • O'Brien, Susan;
    • Steensma, David P.;
    • Sekeres, Mikkael A.;
    • Gore, Steven D.;
    • Dezern, Amy;
    • Roboz, Gail J.;
    • List, Alan F.;
    • Kantarjian, Hagop M.;
    • Komrokji, Rami S.
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

    Published in:
    Journal of Hematology & Oncology, 2017, v. 10, p. 1, doi. 10.1186/s13045-017-0491-2
    By:
    • Fenaux, Pierre;
    • Giagounidis, Aristoteles;
    • Selleslag, Dominik;
    • Beyne-Rauzy, Odile;
    • Mittelman, Moshe;
    • Muus, Petra;
    • Nimer, Stephen D.;
    • Hellström-Lindberg, Eva;
    • Powell, Bayard L.;
    • Guerci-Bresler, Agnes;
    • Sekeres, Mikkael A.;
    • Deeg, H. Joachim;
    • del Cañizo, Consuelo;
    • Greenberg, Peter L.;
    • Shammo, Jamile M.;
    • Skikne, Barry;
    • Xujie Yu;
    • List, Alan F.
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39
    40

    A model for prediction of FLT3- ITD and NPM1 (without FLT3- ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.

    Published in:
    British Journal of Haematology, 2013, v. 163, n. 1, p. 130, doi. 10.1111/bjh.12450
    By:
    • Ostronoff, Fabiana;
    • Othus, Megan;
    • Kantarjian, Hagop M.;
    • Meshinchi, Soheil;
    • Ravandi, Farhad;
    • Hendrie, Paul C.;
    • Faderl, Stefan;
    • Becker, Pamela S.;
    • Cortes, Jorge E.;
    • Pagel, John M.;
    • Petersdorf, Stephen H.;
    • Godwin, John E.;
    • Willman, Cheryl L.;
    • Pierce, Sherry A.;
    • List, Alan F.;
    • Sandhu, Ravinder K.;
    • Walter, Roland B.;
    • Stirewalt, Derek L.;
    • Appelbaum, Frederick R.;
    • Estey, Elihu H.
    Publication type:
    Article
    41
    42
    43
    44

    Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.

    Published in:
    British Journal of Haematology, 2010, v. 148, n. 1, p. 48, doi. 10.1111/j.1365-2141.2009.07919.x
    By:
    • Chauncey, Thomas R.;
    • Gundacker, Holly;
    • Shadman, Mazyar;
    • List, Alan F.;
    • Dakhil, Shaker R.;
    • Erba, Harry P.;
    • Slovak, Marilyn L.;
    • I-Ming Chen;
    • Willman, Cheryl L.;
    • Kopecky, Kenneth J.;
    • Appelbaum, Frederick R.
    Publication type:
    Article
    45
    46
    47
    48
    49
    50